Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 73, No 2 (2023)
Research paper (original)
Published online: 2023-04-27
View PDF Download PDF file
Get Citation

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

Tomasz Olesiński1, Marek Szpakowski1, Wojciech Każmierczak1, Urszula Sulkowska2, Andrzej Rutkowski1
DOI: 10.5603/NJO.2023.0016
·
Nowotwory. Journal of Oncology 2023;73(2):68-72.
Affiliations
  1. Division I of the Department of Surgery for Tumors of the Gastrointestinal System and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Mazovian Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 73, No 2 (2023)
Original article
Published online: 2023-04-27

Abstract

Introduction.The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement.

Material and methods.312 patients with EGJC after R0 surgery were analyzed; 118 (38%) women and 194 (62%) men, median age 58 (29–80) years. In 81 (25.27%) cases, metastases were found in splenic lymph nodes (gr. 10).

Results.in stage I and II A (IA and IB), no metastases were found in splenic hilar lymph nodes (0/42 and 0/18, respectively), in stage IIB 9.61% (5/52), in IIIA 21.74% (15/69), in IIIB 36.36% (16/44), in IIIC 46.83% (37/79), and in stage IV 100% (8/8).

Conclusions.The highest risk of metastasis of esophagogastric junction cancer to splenic hilar lymph nodes exists in caners stage III and IV. Spleen-sparing elective splenectomy or group 10 lymphadenectomy may be of importance in the treatment of patients with stage III and IV gastroesophageal junction cancer, however, the assessment of its usefulness requires further prospective clinical trials.

Abstract

Introduction.The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement.

Material and methods.312 patients with EGJC after R0 surgery were analyzed; 118 (38%) women and 194 (62%) men, median age 58 (29–80) years. In 81 (25.27%) cases, metastases were found in splenic lymph nodes (gr. 10).

Results.in stage I and II A (IA and IB), no metastases were found in splenic hilar lymph nodes (0/42 and 0/18, respectively), in stage IIB 9.61% (5/52), in IIIA 21.74% (15/69), in IIIB 36.36% (16/44), in IIIC 46.83% (37/79), and in stage IV 100% (8/8).

Conclusions.The highest risk of metastasis of esophagogastric junction cancer to splenic hilar lymph nodes exists in caners stage III and IV. Spleen-sparing elective splenectomy or group 10 lymphadenectomy may be of importance in the treatment of patients with stage III and IV gastroesophageal junction cancer, however, the assessment of its usefulness requires further prospective clinical trials.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

gastric cancer; esophagogastric junction cancer; lymphadenectomy; splenectomy

About this article
Title

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 73, No 2 (2023)

Article type

Research paper (original)

Pages

68-72

Published online

2023-04-27

Page views

1792

Article views/downloads

152

DOI

10.5603/NJO.2023.0016

Bibliographic record

Nowotwory. Journal of Oncology 2023;73(2):68-72.

Keywords

gastric cancer
esophagogastric junction cancer
lymphadenectomy
splenectomy

Authors

Tomasz Olesiński
Marek Szpakowski
Wojciech Każmierczak
Urszula Sulkowska
Andrzej Rutkowski

References (30)
  1. Kasakura Y, Fujii M, Mochizuki F, et al. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer? Am J Surg. 2000; 179(3): 237–242.
    CrossRefPubMed
  2. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg. 1997; 84(11): 1567–1571.
    CrossRefPubMed
  3. Degiuli M, Sasako M, Ponzetto A, et al. Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol. 1997; 23(4): 310–314.
    CrossRefPubMed
  4. Hansson LE, Ekström AM, Bergström R, et al. Surgery for stomach cancer in a defined Swedish population: current practices and operative results. Swedish Gastric Cancer Study Group. Eur J Surg. 2000; 166(10): 787–795.
    CrossRefPubMed
  5. Yasuda K, Shiraishi N, Adachi Y, et al. Risk factors for complications following resection of large gastric cancer. Br J Surg. 2001; 88(6): 873–877.
    CrossRefPubMed
  6. Chikara K, Hiroshi S, Masato N, et al. Indications for pancreaticosplenectomy in advanced gastric cancer. Hepatogastroenterology. 2001; 48(39): 908–912.
    PubMed
  7. Csendes A, Burdiles P, Rojas J, et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002; 131(4): 401–407.
    CrossRefPubMed
  8. Schmid A, Thybusch A, Kremer B, et al. Differential effects of radical D2-lymphadenectomy and splenectomy in surgically treated gastric cancer patients. Hepatogastroenterology. 2000; 47(32): 579–585.
    PubMed
  9. Takahashi M, Fujimoto S, Kobayashi K, et al. Indication for splenectomy combined with total gastrectomy for gastric cancer: analisis of data on 249 gastric cancer patients. Hepatogastroenterology. 1995; 42(3): 230–233.
    PubMed
  10. Griffith JP, Sue-Ling HM, Martin I, et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995; 36(5): 684–690.
    CrossRefPubMed
  11. Sano T, Sasako M, Mizusawa J, et al. Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017; 265(2): 277–283.
    CrossRefPubMed
  12. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021; 24(1): 1–21.
    CrossRefPubMed
  13. Pierzankowski I, Dmitruk A, Rybski S, et al. The influence of surgery quality on the longtime results of gastric cancer combination therapy. Nowotwory. Journal of Oncology. 2022; 72(4): 219–225.
    CrossRef
  14. Lo SS, Wu CW, Shen KH, et al. Higher morbidity and mortality after combined total gastrectomy and pancreaticosplenectomy for gastric cancer. World J Surg. 2002; 26(6): 678–682.
    CrossRefPubMed
  15. Budisin N, Budisin E, Golubovic A. Early complications following total gastrectomy for gastric cancer. J Surg Oncol. 2001; 77(1): 35–41.
    CrossRefPubMed
  16. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996; 347(9007): 995–999.
    CrossRefPubMed
  17. Ding P, Gao Z, Zheng C, et al. Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study. BMC Cancer. 2019; 19(1): 905.
    CrossRefPubMed
  18. Zhong Q, Chen QY, Xu YC, et al. Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial. Gastric Cancer. 2021; 24(1): 245–257.
    CrossRefPubMed
  19. Son T, Kwon InG, Lee JHo, et al. Impact of splenic hilar lymph node metastasis on prognosis in patients with advanced gastric cancer. Oncotarget. 2017; 8(48): 84515–84528.
    CrossRefPubMed
  20. Zheng G, Liu J, Guo Y, et al. Necessity of prophylactic splenic hilum lymph node clearance for middle and upper third gastric cancer: a network meta-analysis. BMC Cancer. 2020; 20(1): 149.
    CrossRefPubMed
  21. Lin JX, Wang ZK, Huang YQ, et al. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Ann Surg Oncol. 2021; 28(11): 6649–6662.
    CrossRefPubMed
  22. Du J, Shen Y, Yan W, et al. Risk factors of lymph node metastasis in the splenic hilum of gastric cancer patients: a meta-analysis. World J Surg Oncol. 2020; 18(1): 233.
    CrossRefPubMed
  23. Liu K, Chen XZ, Zhang YC, et al. The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China. Surgery. 2021; 169(2): 426–435.
    CrossRefPubMed
  24. Bencivenga M, Torroni L, Verlato G, et al. Lymphadenectomy for gastric cancer at European specialist centres. Eur J Surg Oncol. 2021; 47(5): 1048–1054.
    CrossRefPubMed
  25. Kinoshita T, Okayama T. Is splenic hilar lymph node dissection necessary for proximal gastric cancer surgery? Ann Gastroenterol Surg. 2021; 5(2): 173–182.
    CrossRefPubMed
  26. Bonenkamp JJ, Hermans J, Sasako M, et al. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999; 340(12): 908–914.
    CrossRefPubMed
  27. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006; 7(4): 309–315.
    CrossRefPubMed
  28. Sasako M, Sano T, Yamamoto S, et al. Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359(5): 453–462.
    CrossRefPubMed
  29. Peeters KC, Hundahl SA, Kranenbarg EK, et al. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005; 29(12): 1576–1584.
    CrossRefPubMed
  30. Hundahl SA. Low Maruyama Index Surgery for Gastric Cancer. Scand J Surg. 2016; 95(4): 243–248.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl